Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

GCC Non Invasive Prenatal Testing Market

ID: MRFR/MED/49126-HCR
200 Pages
Nidhi Mandole
March 2026

GCC Non-Invasive Prenatal Testing Market Research Report: Size, Share, Trend Analysis By Test Type (Cell-Free DNA Testing, Biochemical Testing, Combined Screening), By Applications (Fetal Gender Determination, Chromosomal Abnormalities Screening, Rhesus Disease Screening), By Technology (Next Generation Sequencing, Microarray Analysis, Polymerase Chain Reaction) and By End Users (Hospitals, Diagnostic Laboratories, Direct-to-Consumer Companies) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

GCC Non Invasive Prenatal Testing Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

GCC Non Invasive Prenatal Testing Market Summary

As per Market Research Future analysis, the GCC non-invasive prenatal testing market size was estimated at 45.5 USD Million in 2024. The GCC non invasive-prenatal-testing market is projected to grow from 50.4 USD Million in 2025 to 140.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 10.7% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The GCC non-invasive prenatal testing market is poised for substantial growth driven by technological advancements and increasing healthcare expenditure.

  • Technological advancements in non-invasive prenatal testing are enhancing accuracy and efficiency, thereby attracting more healthcare providers.
  • The regulatory support for non-invasive prenatal testing is strengthening, which is likely to facilitate market entry and expansion.
  • Rising awareness and demand for prenatal testing among expectant parents are contributing to the market's growth trajectory.
  • Key market drivers include increasing healthcare expenditure and cultural shifts towards preventive healthcare, which are likely to bolster the adoption of non-invasive prenatal testing.

Market Size & Forecast

2024 Market Size 45.5 (USD Million)
2035 Market Size 140.0 (USD Million)
CAGR (2025 - 2035) 10.76%

Major Players

Illumina (US), Roche (CH), Natera (US), Fulgent Genetics (US), LabCorp (US), Quest Diagnostics (US), HaploX (US), Genomic Health (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

GCC Non Invasive Prenatal Testing Market Trends

The non invasive-prenatal-testing market is experiencing notable growth, driven by increasing awareness among expectant parents regarding prenatal health. This awareness is often linked to the desire for early detection of genetic conditions, which can significantly influence pregnancy management. In the GCC region, healthcare providers are increasingly adopting advanced technologies to enhance the accuracy and reliability of these tests. The integration of innovative methodologies is likely to improve patient outcomes and foster greater trust in non invasive testing options. Moreover, the regulatory landscape in the GCC is evolving, with governments emphasizing the importance of maternal and fetal health. This shift is encouraging healthcare facilities to invest in non invasive prenatal testing solutions. As a result, the market is poised for expansion, with a growing number of healthcare professionals advocating for these tests as a standard part of prenatal care. The combination of technological advancements and supportive policies may lead to increased accessibility and affordability of non invasive prenatal testing services, ultimately benefiting a larger segment of the population in the region.

Technological Advancements

The non invasive-prenatal-testing market is witnessing rapid technological advancements that enhance test accuracy and efficiency. Innovations in genetic sequencing and bioinformatics are enabling more precise detection of chromosomal abnormalities. These developments are likely to attract more healthcare providers to adopt non invasive testing methods, thereby expanding the market.

Regulatory Support

Regulatory bodies in the GCC are increasingly recognizing the importance of non invasive prenatal testing. This support is manifesting in the form of guidelines and policies that promote the integration of these tests into standard prenatal care. Such regulatory backing may facilitate wider acceptance and utilization of non invasive testing among healthcare professionals.

Rising Awareness and Demand

There is a growing awareness among expectant parents regarding the benefits of non invasive prenatal testing. This heightened awareness is driving demand for these services, as parents seek to ensure the health and well-being of their unborn children. The increasing emphasis on informed decision-making in prenatal care is likely to further propel the market.

GCC Non Invasive Prenatal Testing Market Drivers

Increasing Healthcare Expenditure

The rising healthcare expenditure in the GCC region is a pivotal driver for the non invasive-prenatal-testing market. As governments and private sectors allocate more funds towards healthcare, the accessibility and affordability of advanced medical technologies improve. In 2025, healthcare spending in the GCC is projected to reach approximately $100 billion, reflecting a growth rate of around 5% annually. This increase in funding allows for the integration of innovative prenatal testing solutions, enhancing the quality of maternal care. Furthermore, as healthcare facilities upgrade their services, the demand for non invasive prenatal testing is likely to rise, as it offers a safer alternative to traditional methods. This trend indicates a shift towards preventive healthcare, where early detection of genetic disorders becomes a priority, thereby propelling the non invasive-prenatal-testing market forward.

Government Initiatives and Policies

Government initiatives and policies are instrumental in driving the non invasive-prenatal-testing market. In the GCC, various health authorities are implementing policies that promote the use of advanced prenatal testing methods. These initiatives often include funding for research and development, as well as subsidies for healthcare providers to offer non invasive tests at reduced costs. For instance, the introduction of national health programs aimed at improving maternal health outcomes has led to increased availability of non invasive prenatal testing services. By 2025, it is projected that such government support could enhance market penetration by up to 25%, as more healthcare facilities adopt these technologies. This proactive approach not only improves access to essential services but also encourages public trust in non invasive testing methods.

Rising Birth Rates and Maternal Age

Rising birth rates and an increase in maternal age are contributing factors to the growth of the non invasive-prenatal-testing market. In the GCC, demographic trends indicate that women are choosing to have children later in life, which correlates with a higher risk of genetic disorders. Consequently, there is a heightened demand for reliable prenatal testing options that can provide peace of mind to expectant parents. As of 2025, the birth rate in the region is expected to stabilize around 20 births per 1,000 people, while the average maternal age is projected to rise to 30 years. This demographic shift is likely to drive the adoption of non invasive prenatal tests, as parents seek to mitigate potential health risks associated with advanced maternal age. The market is poised for growth as these trends continue to evolve.

Technological Innovations in Testing

Technological innovations play a crucial role in shaping the non invasive-prenatal-testing market. The introduction of advanced genomic sequencing technologies has significantly improved the accuracy and reliability of prenatal tests. For instance, next-generation sequencing (NGS) has emerged as a leading method, allowing for the analysis of fetal DNA with unprecedented precision. In the GCC, the adoption of such technologies is expected to increase, driven by the demand for non invasive testing methods that minimize risks to both mother and child. As of 2025, the market for NGS in prenatal testing is anticipated to grow by over 20% annually, reflecting the increasing preference for non invasive options. This technological evolution not only enhances diagnostic capabilities but also fosters greater confidence among expectant parents, thereby stimulating market growth.

Cultural Shifts Towards Preventive Healthcare

Cultural shifts towards preventive healthcare are significantly influencing the non invasive-prenatal-testing market. In the GCC, there is a growing recognition of the importance of early detection and intervention in maternal and fetal health. This shift is partly attributed to increased awareness campaigns and educational initiatives that emphasize the benefits of non invasive testing. As a result, more expectant parents are opting for these tests to ensure the health and well-being of their unborn children. The non invasive-prenatal-testing market is likely to benefit from this cultural transformation, as it aligns with the broader trend of prioritizing preventive measures in healthcare. By 2025, it is estimated that the uptake of non invasive prenatal tests could rise by 30%, reflecting a significant change in attitudes towards prenatal care in the region.

Market Segment Insights

By Test Type: Cell-Free Fetal DNA Testing (Largest) vs. Ultrasound Screening (Fastest-Growing)

In the GCC non invasive-prenatal-testing market, the segment values exhibit a notable distribution in market share. Cell-Free Fetal DNA Testing emerges as the largest segment, commanding significant attention due to its high accuracy and reliability. Following this, Biochemical Markers Testing and Ultrasound Screening hold comparatively lesser shares, though they play critical roles within the overall testing framework. The competitive landscape is driven by stakeholders focusing on innovative solutions to enhance testing experiences. Growth trends within this segment are propelled by increased awareness and demand for non-invasive procedures. Cell-Free Fetal DNA Testing is gaining popularity as expectant parents seek safer, more accurate prenatal information. Ultrasound Screening is also witnessing rapid growth as technological advancements enhance imaging capabilities and detection accuracy. The combination of rising healthcare spending and expanding access to these testing modalities is expected to drive continued growth in the GCC non invasive-prenatal-testing market.

Cell-Free Fetal DNA Testing (Dominant) vs. Ultrasound Screening (Emerging)

Cell-Free Fetal DNA Testing is positioned as the dominant testing method in the GCC non invasive-prenatal-testing market, thanks to its unparalleled accuracy in detecting fetal anomalies and genetic conditions. This method utilizes maternal blood samples to analyze cell-free fetal DNA, providing results that are non-invasive and safe for both mother and child. In contrast, Ultrasound Screening represents an emerging segment, rapidly gaining traction as advancements in ultrasound technology improve diagnostic capabilities. While it is less accurate than DNA testing for certain conditions, its imaging allows for visualization of fetal development, thereby contributing to prenatal care. Both methods coexist, catering to varied patient needs and influencing market dynamics significantly.

By Application: Trisomy Detection (Largest) vs. Sex Chromosome Abnormalities (Fastest-Growing)

In the GCC non invasive-prenatal-testing market, Trisomy Detection holds the largest market share, driven by increasing awareness and demand for early genetic testing among expectant parents. This segment is prominent due to its ability to identify common chromosomal abnormalities such as Down syndrome effectively. Conversely, the Sex Chromosome Abnormalities segment is experiencing rapid growth, fueled by technological advancements that enhance detection capabilities, making it a vital option for those seeking information about potential genetic conditions. The growth trends in the application segment indicate a rising preference for non-invasive testing methods that promise accuracy and safety. Additionally, the increasing number of pregnancies and the demand for personalized healthcare solutions contribute to the expansion of these sectors. As healthcare providers continue to promote early screening, both Trisomy Detection and Sex Chromosome Abnormalities are becoming integral to prenatal care in the region, aligning with the broader trend of preventative health measures.

Trisomy Detection: Dominant vs. Sex Chromosome Abnormalities: Emerging

Trisomy Detection is positioned as the dominant force in the GCC non invasive-prenatal-testing market, largely contributing to the declining rates of fetal abnormalities through early detection and intervention. Its established procedures and robust clinical backing provide it with unparalleled credibility among healthcare providers and expectant parents alike. On the other hand, Sex Chromosome Abnormalities serves as an emerging category, gaining traction due to enhancements in diagnostic technologies and a growing recognition of the importance of identifying such conditions. While Trisomy Detection offers broadly applicable insights into common congenital issues, the emerging segment of Sex Chromosome Abnormalities is carving out a distinct niche, catering to a specific need for detailed genetic understanding in prenatal diagnostics.

By Technology: Next-Generation Sequencing (Largest) vs. Massively Parallel Sequencing (Fastest-Growing)

The technology segment of the GCC non invasive-prenatal-testing market showcases a diverse distribution among its primary methodologies. Next-Generation Sequencing (NGS) holds the largest share, demonstrating a significant preference among healthcare providers due to its comprehensive genetic analysis capabilities. In contrast, Microarray Analysis, while reputable, is witnessing a decline in market share as NGS becomes increasingly popular for advanced prenatal testing. Massively Parallel Sequencing, a subset of NGS, is quickly gaining traction as a preferred option, appealing to innovative laboratories seeking higher throughput and efficiency. Growth trends in the technology segment are largely driven by advancements in genetic research and the rising awareness of prenatal genetic conditions. As healthcare professionals increasingly recognize the importance of accurate prenatal testing, the demand for technologies like NGS and Massively Parallel Sequencing is expected to rise. This trend is further bolstered by technological innovations that enhance testing accuracy and reduce turnaround times. The increasing prevalence of genetic disorders and the push for personalized medicine are also significant factors contributing to the upward trajectory of the market.

Technology: Next-Generation Sequencing (Dominant) vs. Massively Parallel Sequencing (Emerging)

Next-Generation Sequencing (NGS) is the dominant technology in the GCC non invasive-prenatal-testing market, renowned for its capability to provide detailed genetic insights. It allows for high-throughput sequencing, enabling extensive analysis of fetal DNA without invasive procedures. This technology not only enhances accuracy in detecting genetic abnormalities but also offers comprehensive insights into a wide range of conditions. Conversely, Massively Parallel Sequencing, although an emerging player, is capturing attention for its efficiency and ability to analyze multiple sequences simultaneously. Laboratories favor this approach for its speed and the potential to handle large volumes of samples, thus positioning it as a key contender in the evolving landscape of prenatal testing technology.

By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the GCC non invasive-prenatal-testing market, hospitals hold a significant share of the end-user segment, attributed to their extensive resources and ability to provide comprehensive care. They are the primary providers of prenatal testing services, leveraging advanced technologies and skilled professionals to ensure accurate results. On the other hand, diagnostic laboratories are experiencing rapid growth, capturing an increasing share as they adopt innovative testing methods and boost their service offerings to meet the rising demand from expectant parents. The growth trends within this market segment are primarily driven by an increasing awareness of prenatal health and a shift towards non-invasive procedures. Hospitals are expanding their capabilities by integrating new technologies, while diagnostic laboratories are enhancing their operational efficiencies to cater to a broader clientele. Research institutions also play a notable role in advancing prenatal testing methodologies, fostering collaborations that further stimulate market growth, and leading to the ongoing development of cutting-edge solutions that support clinicians and patients alike.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals represent the dominant force in the end-user segment of the GCC non invasive-prenatal-testing market, primarily due to their established infrastructure and reputation for reliability. They offer a wide range of services, including genetic counseling and various prenatal tests, positioning themselves as trusted sources for expectant families. In contrast, diagnostic laboratories are emerging players that leverage technology to develop quicker and more efficient testing processes. As they evolve, these laboratories are increasingly partnering with hospitals and healthcare providers to offer specialized services, contributing to their accelerated growth in this dynamic market. The competition between these two segments is fostering innovation, leading to improved testing accuracy and better patient outcomes.

Non-Invasive Prenatal Testing Market End User Insights

Non-Invasive Prenatal Testing Market End User Insights

The ser segment of the GCC Non-Invasive Prenatal Testing Market plays a crucial role in the market's overall dynamics, with various entities such as Hospitals, Diagnostic Laboratories, and Direct-to-Consumer Companies shaping its landscape. Hospitals are notable for their comprehensive care capabilities, often serving as the primary point of access for patients seeking prenatal testing. These facilities typically integrate advanced non-invasive testing methods into their routine prenatal care, thus enhancing patient experience and outcomes.Diagnostic Laboratories are integral as well, offering specialized testing services that are crucial for accurate and timely results.

These laboratories often utilize cutting-edge technologies, ensuring that clinicians and expectant parents receive reliable data to inform their health decisions. Meanwhile, Direct-to-Consumer Companies are transforming the market by offering accessible genetic testing solutions directly to consumers, empowering them with the information needed to make informed decisions about their pregnancies.

This trend reflects a growing consumer demand for personalized healthcare options and contributes to the increasing adoption of non-invasive methodologies in prenatal testing across the GCC region.The diverse interplay between these end users is indicative of a dynamic marketplace that is adapting to technological advancements and changing consumer preferences, leading to significant strides in maternal-fetal health.

Get more detailed insights about GCC Non Invasive Prenatal Testing Market
Request Free Sample

Key Players and Competitive Insights

The non invasive-prenatal-testing market is characterized by a dynamic competitive landscape, driven by technological advancements and increasing consumer demand for early and accurate prenatal diagnostics. Key players such as Illumina (US), Roche (CH), and Natera (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Illumina (US) focuses on innovation through continuous investment in genomic technologies, while Roche (CH) emphasizes strategic partnerships to expand its product offerings. Natera (US) is leveraging its expertise in genetic testing to enhance its service portfolio, indicating a trend towards specialization in the market. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological differentiation and customer-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to emerge, fostering innovation and competition. The collective influence of these major companies shapes the market dynamics, as they vie for leadership through strategic initiatives and operational excellence.

In October Illumina (US) announced a collaboration with a leading healthcare provider to integrate its advanced genomic sequencing technology into routine prenatal care. This strategic move is likely to enhance accessibility to cutting-edge testing solutions, positioning Illumina (US) as a leader in the integration of genomics into clinical practice. The collaboration underscores the importance of partnerships in expanding market reach and improving patient outcomes.

In September Roche (CH) launched a new non invasive prenatal test that utilizes artificial intelligence to enhance the accuracy of genetic risk assessments. This innovation not only strengthens Roche's product portfolio but also reflects a broader trend towards the integration of AI in healthcare solutions. The strategic importance of this launch lies in its potential to set new standards for accuracy and reliability in prenatal testing, thereby attracting a larger customer base.

In August Natera (US) expanded its operations into the GCC region by establishing a new laboratory facility aimed at increasing its testing capacity. This expansion is indicative of Natera's commitment to meeting the growing demand for prenatal testing in emerging markets. By localizing operations, Natera (US) can enhance service delivery and reduce turnaround times, which are critical factors in patient satisfaction and market competitiveness.

As of November current trends in the non invasive-prenatal-testing market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a focus on technological innovation, reliability in supply chains, and enhanced customer experiences. This transition suggests that companies that prioritize these aspects will likely gain a competitive edge in the rapidly evolving market.

Key Companies in the GCC Non Invasive Prenatal Testing Market include

Industry Developments

The GCC Non-Invasive Prenatal Testing Market has witnessed significant developments recently, with a notable increase in demand for advanced prenatal screening solutions. Companies such as Grail and Natera are focusing on enhancing their product offerings amid rising awareness regarding prenatal health. Illumina and Roche Diagnostics are expanding their services in the region by collaborating with local healthcare providers to facilitate wider access to non-invasive prenatal tests. In terms of market valuation, Genetic Technologies and Myriad Genetics have reported growth driven by technological advancements and increasing birth rates in GCC countries.

In November 2022, Quest Diagnostics announced a strategic partnership with Sema4 to broaden their testing capabilities across the GCC region, which aims to harmonize efforts towards precision medicine. Additionally, multiple firms, including Invitae Corporation and CooperSurgical, are focusing on Research and Development to introduce novel testing methodologies, which expected to bolster market growth. The surge in market activities over the past two years reveals a continuous effort to push for improved prenatal health services across the GCC, thereby transforming healthcare delivery in this sector.

Overall, the market dynamics are evolving with the integration of technology and collaboration among key players in the industry.

Future Outlook

GCC Non Invasive Prenatal Testing Market Future Outlook

The Non Invasive Prenatal Testing Market is projected to grow at a 10.76% CAGR from 2025 to 2035, driven by technological advancements, increasing awareness, and rising demand for early diagnosis.

New opportunities lie in:

  • Development of mobile testing units for remote areas
  • Partnerships with healthcare providers for integrated services
  • Investment in AI-driven data analytics for personalized testing solutions

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

Market Segmentation

GCC Non Invasive Prenatal Testing Market End User Outlook

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions

GCC Non Invasive Prenatal Testing Market Test Type Outlook

  • Cell-Free Fetal DNA Testing
  • Biochemical Markers Testing
  • Ultrasound Screening

GCC Non Invasive Prenatal Testing Market Technology Outlook

  • Next-Generation Sequencing
  • Microarray Analysis
  • Massively Parallel Sequencing

GCC Non Invasive Prenatal Testing Market Application Outlook

  • Trisomy Detection
  • Single Gene Disorders
  • Sex Chromosome Abnormalities

Report Scope

MARKET SIZE 2024 45.5(USD Million)
MARKET SIZE 2025 50.4(USD Million)
MARKET SIZE 2035 140.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 10.76% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Illumina (US), Roche (CH), Natera (US), Fulgent Genetics (US), LabCorp (US), Quest Diagnostics (US), HaploX (US), Genomic Health (US)
Segments Covered Test Type, Application, Technology, End User
Key Market Opportunities Advancements in genetic testing technologies enhance accuracy and accessibility in the non invasive-prenatal-testing market.
Key Market Dynamics Rising demand for accurate prenatal diagnostics drives innovation and competition in the non invasive-prenatal-testing market.
Countries Covered GCC
Author
Author
Author Profile
Nidhi Mandole LinkedIn
Senior Research Analyst
She is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Nidhi is comfortably versed in data centric research backed by healthcare educational background. She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. Her key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, she showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

FAQs

What is the projected market valuation for the GCC non invasive-prenatal-testing market by 2035?

<p>The projected market valuation for the GCC non invasive-prenatal-testing market is $140.0 Million by 2035.</p>

What was the overall market valuation in 2024?

<p>The overall market valuation in 2024 was $45.5 Million.</p>

What is the expected CAGR for the GCC non invasive-prenatal-testing market during the forecast period 2025 - 2035?

<p>The expected CAGR for the GCC non invasive-prenatal-testing market during the forecast period 2025 - 2035 is 10.76%.</p>

Which companies are considered key players in the GCC non invasive-prenatal-testing market?

<p>Key players in the market include Illumina, Roche, Natera, Fulgent Genetics, LabCorp, Quest Diagnostics, HaploX, and Genomic Health.</p>

What are the main test types in the GCC non invasive-prenatal-testing market and their valuations?

<p>The main test types include Cell-Free Fetal DNA Testing valued at $65.0 Million, Biochemical Markers Testing at $45.0 Million, and Ultrasound Screening at $30.0 Million.</p>

What applications are driving the GCC non invasive-prenatal-testing market?

<p>Applications driving the market include Trisomy Detection valued at $60.0 Million, Single Gene Disorders at $45.0 Million, and Sex Chromosome Abnormalities at $35.0 Million.</p>

What technologies are utilized in the GCC non invasive-prenatal-testing market?

<p>Technologies utilized include Next-Generation Sequencing valued at $65.0 Million, Microarray Analysis at $45.0 Million, and Massively Parallel Sequencing at $30.0 Million.</p>

Who are the primary end users of non invasive-prenatal-testing in the GCC market?

<p>Primary end users include Diagnostic Laboratories valued at $70.0 Million, Hospitals at $46.0 Million, and Research Institutions at $24.0 Million.</p>

How does the market for Cell-Free Fetal DNA Testing compare to other test types?

<p>Cell-Free Fetal DNA Testing leads with a valuation of $65.0 Million, surpassing Biochemical Markers Testing at $45.0 Million and Ultrasound Screening at $30.0 Million.</p>

What trends are expected to shape the GCC non invasive-prenatal-testing market in the coming years?

<p>Trends likely to shape the market include advancements in technology and increasing demand for non invasive testing methods, contributing to the projected growth.</p>

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓